Maharashtra FDA launches prosecution against Trisis Ventures for non compliance to Drugs and Cosmetics Act
The Maharashtra Food and Drug Administration (FDA) has launched prosecution against Trisis Ventures in Judicial Magistrate First Class (JMFC) Court, Bhiwandi for manufacturing disinfectant without license.
This according to FDA officials is in contravention to the provision of Section 18 (c) of Drugs and Cosmetics (D&C) Act, 1940.
Thane FDA team led by Drugs Inspector A A Raskar seized stock worth of Rs.11.11 crore of disinfectant Virkon S from a godown in Bhiwandi.
The said disinfectant brand was manufactured in Baddi, Himachal Pradesh without licence.
Also read: FDA to set up DPCO violation cell
According to D&C Act 1940 under section 18 (C), any person who violates it and sells drugs without a valid license as required under clause C of section 18 shall be punishable with imprisonment for a term which shall not be less than one year but which may extend to three years and with fine which shall not be less than five thousand rupees.
In a series of crackdown for violation of drug, the state drug regulator recently also detected an online illegal abortion drug racket.
As a part of the crackdown, the state FDA has revealed that Medical Termination of Pregnancy (MTP) pills which is a scheduled drug was traded online in contravention to the law of the land.
Also read: Punjab FDA seized drugs worth Rs 4 crore
MTP is a schedule H drug and can be taken only against the prescription of a qualified gynaecologist.
MTP Kit is a set of two essential abortion medicines -Mifepristone and Misoprostol which performs medical pregnancy termination (non-surgical embryo expel from womb) and should be taken only under the supervision and prescription of a gynaecologist.
This is the latest in the series of such cases where offenders used to stock and sell MTP kits in a clandestine manner without a license and trade it online.